Ohtuvayre is due to launch in the US in the third quarter of this year, assisted by a $650 million debt facility that Verona agreed a few months ago to build its commercial capabilities.

Verona Pharma operates in a competitive COPD market, but Ohtuvayre’s differentiated mechanism of action and competitive pricing strategy position it well against established players. The product ...

Verona Pharma (VRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on the ...

Verona Pharma stock hit a record high Thursday — running up 19% over the past four days — on continued enthusiasm for its COPD treatment, Ohtuvayre. Please watch the video at Investors.com ...

“2024 was another transformational year for Verona with the approval and US launch of Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (“COPD ...

Verona Pharma reports $36M in Q4 and $42M in 2024 sales for Ohtuvayre, with over 16,000 prescriptions filled. Verona Pharma plc has announced its preliminary unaudited net product sales for ...

LONDON and RALEIGH, N.C., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) ("Verona Pharma” or the "Company ...

For further information please contact: Verona P Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3 Through October more than 2,200 unique ...

Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for ...

In Nov 2024, Nuance Pharma launched Ohtuvayre™ in China's Hainan Boao Pilot Zone through early access program. In Sep 2024, Nuance Pharma completed recruitment for ENHANCE- CHINA, the phase 3 clinical ...